• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Testosterone Treatments Aren ’ t Linked to Heart Risks When Patients Are Carefully Monitored, Study Finds
Advertisements for treatments for “low T,” or low testosterone levels in middle-aged and older men, have led to spikes in demand. But the safety and legitimacy of those testosterone therapies hasn’t been clear. In a new study published in the New England Journal of Medicine and presented at the Endocrine Society’s annual meeting, researchers provide the most conclusive evidence yet that testosterone treatments appear to be safe for the heart and are not associated with an increased risk of certain heart-related events. In the study, led by researchers at the Cleveland Clinic, more than 5,200 men age...
Source: TIME: Health - June 16, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthscienceclimate heart health Source Type: news

Menopausal hormone therapy and risk of cardiovascular events in women with prediabetes or type 2 diabetes: A pooled analysis of 2917 postmenopausal women
CONCLUSIONS: MHT is associated with statistically reduced CVD risk among white but not black women with PreDM or DM. Race is an effect modifier in the association between MHT use and CVD.PMID:35114556 | DOI:10.1016/j.atherosclerosis.2022.01.016
Source: Atherosclerosis - February 3, 2022 Category: Cardiology Authors: Yilin Yoshida Zhipeng Chen Robin L Baudier Marie Krousel-Wood Amanda H Anderson Vivian A Fonseca Franck Mauvais-Jarvis Source Type: research

Transgender People Often Have Heart Risks: Study
THURSDAY, Nov. 12, 2020 -- Many transgender people who take hormone therapy have unaddressed risks for heart disease and stroke, a new study finds. These patients often have undiagnosed high blood pressure and high cholesterol, even in young...
Source: Drugs.com - Daily MedNews - November 12, 2020 Category: General Medicine Source Type: news

The Women's Health Initiative Estrogen-alone Trial had differential disease and medical expenditure consequences across age groups
Conclusion: The decline in ET utilization had differential disease and expenditure consequences by age groups in the United States. These results are limited by the lack of inclusion of vasomotor symptom benefit and costs of alternative medications for these symptoms in the analysis.
Source: Menopause - May 29, 2020 Category: OBGYN Tags: Original Studies Source Type: research

Cardiovascular Risk/Benefit Profile of MHT.
Conclusion: CV risk calculation should be considered by clinicians in order to exclude patients with high CV risk, in whom MHT is contraindicated. Assessing risks and benefits in a patient-centered approach according to individual's features, health status, and personal preferences is important in order to realize a safe and effective treatment. PMID: 31500138 [PubMed - in process]
Source: Medicina (Kaunas) - September 5, 2019 Category: Universities & Medical Training Authors: Villa P, Amar ID, Shachor M, Cipolla C, Ingravalle F, Scambia G Tags: Medicina (Kaunas) Source Type: research

Cardiovascular Programming During and After Diabetic Pregnancy: Role of Placental Dysfunction and IUGR
This study demonstrated that the incidence of ischemic heart disease and death were three times higher among men with low birth weight compared to men with high birth weight (5). Epidemiological investigations of adults born at the time of the Dutch famine between 1944 and 1945 revealed an association between maternal starvation and a low infant birth weight with a high incidence of hypertension and coronary heart disease in these adults (23). Furthermore, Painter et al. reported the incidence of early onset coronary heart disease among persons conceived during the Dutch famine (24). In that regard, Barker's findin...
Source: Frontiers in Endocrinology - April 8, 2019 Category: Endocrinology Source Type: research

The 2017 hormone therapy position statement of The North American Menopause Society
The 2017 Hormone Therapy Position Statement of The North American Menopause Society (NAMS) updates the 2012 Hormone Therapy Position Statement of The North American Menopause Society and identifies future research needs. An Advisory Panel of clinicians and researchers expert in the field of women's health and menopause was recruited by NAMS to review the 2012 Position Statement, evaluate new literature, assess the evidence, and reach consensus on recommendations, using the level of evidence to identify the strength of recommendations and the quality of the evidence. The Panel's recommendations were reviewed and approved by...
Source: Menopause - October 25, 2018 Category: OBGYN Tags: Commemorative Papers Source Type: research

In assessing risk of hormone therapy for menopause, dose — not form — matters
FINDINGSWhen it comes to assessing the risk of estrogen therapy for menopause, how the therapy is delivered — taking a pill versus wearing a patch on one’s skin — doesn’t affect risk or benefit, researchers at UCLA and elsewhere have found. But with the commonly used conjugated equine estrogen, plus progestogen, the dosage does. Higher doses, especially over time, are associated with greater risk of problems, including heart disease and some types of cancer, especially among obese women.BACKGROUNDThe Women ’s Health Initiative established the potential of estrogen therapy to increase or decrease the risk of strok...
Source: UCLA Newsroom: Health Sciences - July 27, 2017 Category: Universities & Medical Training Source Type: news

Does coffee make you live longer?
Conclusion This study, conducted on a large number of people across Europe, was backed up by similar findings in the US. It appears to show some association between people who drink higher amounts of coffee and a reduced risk of death. But the "potentially beneficial clinical implications" need to be considered carefully for a number of reasons: Although the analyses were adjusted for some confounding variables, there may be a number of other factors that differ between the groups that account for the differences in death, such as socioeconomic status, family history, other medical conditions, and use of medic...
Source: NHS News Feed - July 12, 2017 Category: Consumer Health News Tags: Food/diet Source Type: news

The 2017 hormone therapy position statement of The North American Menopause Society
Abstract: The 2017 Hormone Therapy Position Statement of The North American Menopause Society (NAMS) updates the 2012 Hormone Therapy Position Statement of The North American Menopause Society and identifies future research needs. An Advisory Panel of clinicians and researchers expert in the field of women's health and menopause was recruited by NAMS to review the 2012 Position Statement, evaluate new literature, assess the evidence, and reach consensus on recommendations, using the level of evidence to identify the strength of recommendations and the quality of the evidence. The Panel's recommendations were reviewed and a...
Source: Menopause - June 27, 2017 Category: OBGYN Tags: Position Statement Source Type: research

Luteolin: How To Reduce Breast Cancer Risk
More than 100 women die of breast cancer in the U.S. every day. It's the second leading cause of cancer deaths in American women. But in my opinion, many of those women really die of a tragic medical error. Let me explain… Millions of women in the U.S. have taken Big Pharma's hormone replacement therapy (HRT). Their doctors prescribe it to try to relieve the symptoms of menopause. Like hot flashes, night sweats, mood swings and weight gain. But what the drug companies try to pass off as hormones are actually synthetic concoctions. They are fake versions of the estrogen and progesterone that your body makes n...
Source: Al Sears, MD Natural Remedies - June 23, 2017 Category: Complementary Medicine Authors: Al Sears Tags: Anti-Aging Source Type: news

Anti-M üllerian Hormone Trajectories Are Associated With Cardiovascular Disease in Women: Results From the Doetinchem Cohort Study.
CONCLUSIONS: These results indicate that AMH trajectories in women are independently associated with CVD risk. Therefore, we postulate that the decline of circulating AMH levels may be part of the pathophysiology of the increased cardiovascular risk of earlier menopause. Confirmation of this association and elucidation of its underlying mechanisms are needed to place these results in a clinical perspective. PMID: 28153992 [PubMed - in process]
Source: Circulation - February 6, 2017 Category: Cardiology Authors: de Kat AC, Verschuren WM, Eijkemans MJ, Broekmans FJ, van der Schouw YT Tags: Circulation Source Type: research

The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms.
Authors: Parish SJ, Gillespie JA Abstract This review describes the evolving role of oral hormone therapy (HT) for treating menopausal symptoms and preventing osteoporosis, focusing on conjugated estrogens/bazedoxifene (CE/BZA). Estrogens alleviate hot flushes and prevent bone loss associated with menopause. In nonhysterectomized women, a progestin should be added to estrogens to reduce the risk of endometrial cancer. Use of HT declined since the Women's Health Initiative (WHI) studies showed that HT does not prevent coronary heart disease (CHD) and that conjugated estrogens/medroxyprogesterone acetate increased th...
Source: Postgraduate Medicine - February 1, 2017 Category: Internal Medicine Tags: Postgrad Med Source Type: research

Withdrawal of hormone therapy and increased risk of cardiovascular disease.
Abstract Many menopause specialists follow the principle of prescribing postmenopausal hormone therapy (HT) for the shortest duration needed, in order to decrease the risk of some related serious adverse effects, such as breast cancer. Based on several large studies, it seems, however, that withdrawal of HT may be associated with immediate, though small increased risk of coronary heart disease and stroke. Cessation of HT correlates with increased risk of fractures as well. This information should be relayed to hormone users while discussing the continuation of HT with their health-care provider, but, since the pot...
Source: Climacteric - April 13, 2016 Category: Geriatrics Authors: Pines A Tags: Climacteric Source Type: research

Can HRT in early menopause cut heart disease risk?
ConclusionThis double-blind RCT found that women taking HRT less than six years after the menopause had slower artery wall thickening than those taking a placebo. This represented the main measure of atherosclerosis progression tested; other measures showed no difference, so the results were not as conclusive as they could have been. Women taking HRT 10 or more years after menopause also showed no difference in atherosclerosis progression compared with a placebo, further complicating the picture.An important limitation of this study is the lack of a patient relevant endpoint, such as cardiovascular events or mortality. Pre...
Source: NHS News Feed - April 1, 2016 Category: Consumer Health News Tags: Heart/lungs Medication Source Type: news

Pages: 1  2  3